474.34MMarket Cap-4181P/E (TTM)
6.840High6.350Low3.42MVolume6.360Open6.270Pre Close22.80MTurnover4.86%Turnover RatioLossP/E (Static)70.90MShares14.84052wk High2.74P/B470.89MFloat Cap2.09052wk Low--Dividend TTM70.39MShs Float978.000Historical High--Div YieldTTM7.82%Amplitude-1731.000Historical Low6.662Avg Price1Lot Size
Altimmune Stock Forum
Altimmune Announces Publication of Clinical Study of Pemvidutide in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Journal of Hepatology
Altimmune (Nasdaq: ALT) has published data from a 12-week clinical trial of pemvidutide, a GLP-1/glucagon dual receptor agonist, in the Journal of Hepatology. The study focused on metabolic dysfunction-associated steatotic liver disease (MASLD). Key findings include:
- Up to 68.5% relative reduction in liver fat con...
Larger Image: tradingview.com...
$Altimmune(ALT.US)$
No comment yet